Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4192176 | 1.00 | NPSR1 (0.39) | NPSR1SMN1; SMN2HSD11B1P2RX3KAT2B | |
| SCHEMBL4192177 | 1.00 | NPSR1 (0.39) | NPSR1SMN1; SMN2HSD11B1P2RX3KAT2B | |
| SCHEMBL4177490 | 0.82 | HSD11B1 (0.45) | NPSR1SMN1; SMN2HSD11B1KAT2BGFER | |
| SCHEMBL4177495 | 0.82 | HSD11B1 (0.45) | NPSR1SMN1; SMN2HSD11B1KAT2BGFER | |
| SCHEMBL4177483 | 0.82 | HSD11B1 (0.45) | NPSR1SMN1; SMN2HSD11B1KAT2BGFER | |
| SCHEMBL4168203 | 0.81 | SMN1; SMN2 (0.40) | NPSR1SMN1; SMN2HSD11B1P2RX3GFER | |
| SCHEMBL4168201 | 0.81 | SMN1; SMN2 (0.40) | NPSR1SMN1; SMN2HSD11B1P2RX3GFER | |
| SCHEMBL4168197 | 0.81 | SMN1; SMN2 (0.40) | NPSR1SMN1; SMN2HSD11B1P2RX3GFER | |
| SCHEMBL7723195 | 0.81 | ALDH1A1 (0.43) | NPSR1SMN1; SMN2HSD11B1SOAT1ALDH1A1 | |
| SCHEMBL6968887 | 0.81 | GFER (0.47) | NPSR1SMN1; SMN2HSD11B1GFERCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | ABCC1, AZI2, TPD52L2 | NPSR1 3113/4885SMN1; SMN2 1918/4885HSD11B1 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.